Effects of microplastics and nanoplastics on the kidneys
doi.org/10.1093/ndt/...
Effects of microplastics and nanoplastics on the kidneys
doi.org/10.1093/ndt/...
The updated global burden of chronic kidney disease: one death every 20 seconds
doi.org/10.1093/ndt/...
What do clinical trials teach us about the pathophysiology of human IgA nephropathy?
π doi.org/10.1093/ndt/...
Oil supplementation and cardiovascular mortality in the dialysis population
doi.org/10.1093/ndt/...
Risk-based referral model to nephrologist specialist care in Stockholm
doi.org/10.1093/ndt/...
The multiple autoantibodies in anti-GBM disease
doi.org/10.1093/ndt/...
πDid you already discover the NDT kidney art gallery?
era-online.org/ndt-kidney-a...
π€©Check it out and send us one of your own kidney images!
π€© Check out the new January issue of NDT!
academic.oup.com/ndt/issue/41/1
Anti-glomerular basement membrane diseaseβtreatment standard
doi.org/10.1093/ndt/...
Membranous nephropathy treatment standard
doi.org/10.1093/ndt/...
How to individualize renoprotective therapy in obese patients with chronic kidney disease:
a commentary by the Diabesity Working Group of the ERA
doi.org/10.1093/ndt/...
When impact trials are not feasible:
alternatives to study the impact of prediction models on clinical practice
doi.org/10.1093/ndt/...
How should we best manage the consequences of nephron loss in IgAN?
doi.org/10.1093/ndt/...
Disease modification in IgA nephropathy
doi.org/10.1093/ndt/...
BK Polyomavirus-associated nephropathy β diagnostic and treatment standard
π doi.org/10.1093/ndt/...
Global, regional, and national burden of renal anemia, 1990 to 2019 and prediction to 2050
doi.org/10.1093/ndt/...
Cardiovascular involvement in ANCA-associated vasculitis
doi.org/10.1093/ndt/...
Prevalence of reduced eGFR in European adults using KDIGO and age-adapted eGFR thresholds
doi.org/10.1093/ndt/...
The nonsteroidal mineralocorticoid receptor blocker esaxerenone reduces glomerular hyperfiltration and albuminuria
doi.org/10.1093/ndt/...
Effectiveness and safety of finerenone in IgA nephropathy patients
doi.org/10.1093/ndt/...
Management of monoclonal gammopathy of renal significance: treatment standard
doi.org/10.1093/ndt/...
Kidney disease after hematopoietic stem cell transplant βtreatment standard
doi.org/10.1093/ndt/...
π€©Check out the new December issue of NDT!
academic.oup.com/ndt/issue/40...
Now online in @ndt-era.bsky.social β this article by Prof Daniel Gale shows how RaDaR data are accelerating drug development for rare kidney diseases β informing NICE appraisals, regulatory endpoints & clinical trials for IgA nephropathy, FSGS, C3G & Alport syndrome.
π: ow.ly/L9HK50XqqqT
Nephrotoxicity of Conventional Chemotherapeutics: Part I β Platinum Compounds and Antimetabolite Agents
doi.org/10.1093/ndt/...
Trends in nephrology: from reducing proteinuria with steroids to curing glomerulonephritis
doi.org/10.1093/ndt/...
Body roundness index and mortality risk in patients with chronic kidney disease: moving beyond the obesity paradox
doi.org/10.1093/ndt/...
Cardio-renoprotective effects of SGLT2 inhibitorsβthe role of anaemia correction
doi.org/10.1093/ndt/...
C3G and Ig-MPGN:
treatment standard
doi.org/10.1093/ndt/...
πTrends in nephrology:
Cardiovascular Kidney-Metabolic syndrome
π doi.org/10.1093/ndt/...